Until just a few decades ago, raised blood pressure was regarded as a benign and natural process of ageing that did not warrant treatment. In the 1966 edition of his textbook Diseases of the Heart, 1 the cardiologist Charles Friedberg noted that treatment of individuals with a blood pressure lower than 200/100 mm Hg was not indicated. Since then, the accumulation of a large body of evidence on raised blood pressure has fundamentally changed clinical practice and health policy worldwide. Large-scale epidemiological studies 2 have proven beyond doubt that long-term exposure to raised blood pressure is associated with a substantially increased risk of cardiovascular disease, with no apparent benign range at any age. An analysis 3 of population-based studies has quantifi ed the absolute burden of blood pressure-associated death and disability, showing that raised blood pressure has been the leading risk factor for cardiovascular death in every region of the world for the past 30 years. Furthermore, a range of eff ective and cost-eff ective interventions for modifying blood pressure-associated risks have been identifi ed. 4, 5 Not only have these fi ndings changed clinical practice and public health but they have also become the foundations of global policies; for example, WHO's Global Action Plan for the prevention of non-communicable diseases 2013-20 specifi es a 25% reduction or containment of the prevalence of raised blood pressure as one of its nine voluntary targets. 6 To what extent have these tremendous achievements been eff ective in reducing the burden of raised blood pressure so far? The most comprehensive and updated answer to this question comes from a report by the NCD Risk Factor Collaboration published in The Lancet. 7 In their study, the authors use population-based surveys involving 19·1 million adults to estimate temporal trends in mean systolic and diastolic blood pressure and the prevalence of raised blood pressure (defi ned as blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic) from 1975 to 2015 in 200 countries. The collaboration found that across all countries, age-standardised mean blood pressure has been largely stagnant in men and decreased only by about 2·5 mm Hg in women, with the change in women occurring before 2000 and no apparent change since.
Although at fi rst glance these static trends seem disappointing, a closer look at the disaggregated results and the comparisons of trends among regions and countries reveals several insights that will help to refocus our eff orts. One key insight is that substantial and continuous reductions in mean blood pressure and prevalence of raised blood pressure are achievable, as evident from the decreasing trends in the highperforming, mainly high-income, regions and countries. However, the opposing trends in several other, mainly low-income and middle-income countries, suggest that these countries are unlikely to achieve substantial reductions in mean age-standardised population-level blood pressure if no additional measures are taken. In fact, the report reminds us that even with containment of age-standardised blood pressure, the absolute number of people aff ected by raised blood pressure is likely to continue to grow in low-income and middleincome countries, mainly because of ageing and population growth, which are only partly counteracted by other trends.
But what are the key drivers of age-standardised blood pressure reductions? Can we learn from the success in high-performing countries to bend the blood pressure curve down in less successful regions and to accelerate reductions in better performing regions? The few available long-term national surveys that started in the 1950s showed that the reduction in mean blood pressure preceded the availability of specifi c interventions targeting it. 8, 9 This fact suggests that a substantial proportion of the change is likely due to population-wide interventions. Such interventions include some now well established factors such as dietary and lifestyle changes, but also some less well measured factors such as early-life nutrition, or emerging exposures such as indoor temperature, air pollution, and noise. In the past three decades, improved medical care and widened use of anti-hypertensive treatments of proven eff ectiveness have made further contributions to blood pressure reductions. 8, 10 However, these treatments remain heavily underused in both rich and poor countries, 2 calling for alternative models of health-care delivery that are less dependent on healthcare professionals and instead make evidence more directly accessible to end-consumers. 11, 12 Eff ective control of raised blood pressure requires collaborative, multisectoral, national eff orts to improve implementation of available evidence. The failure to tackle this issue more decisively will come at a high cost, particularly to disadvantaged individuals and societies. The clear view of recent achievements, as provided by the NCD Risk Factor Collaboration, should help us to collectively steer the action plan more eff ectively and equitably towards decreasing blood pressure globally.
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